"The Company expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO product sales, will be sufficient to fund its planned operations into the middle of 2022"
"The Company expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO product sales, will be sufficient to fund its planned operations into the second half of 2022."
Karyopharm Therapeutics Inc. (KPTI) has secured approval for XPOVIO in Israel for the treatment of patients with either multiple myeloma or diffuse large B-cell lymphoma.
The company has an exclusive distribution agreement with Promedico Ltd. for the commercialization of XPOVIO in Israel and the Palestinian Authority. The drug received its initial approval in the U.S. in July 2019, and is under review by the European Medicines Agency.
Karyopharm is slated to report fourth quarter and full year 2020 financial results on Thursday, February 11, 2021.
The net product sales of XPOVIO are expected to be between $20.0 million and $20.5 million for the fourth quarter of 2020 and between $76.0 million and $76.5 million for the full year of 2020. The sales of XPOVIO were $17.7 million for the fourth quarter and $30.5 million for full year 2019.
KPTI closed Thursday's trading at $14.60, down 1.08%.
"The Company expects that its existing cash, cash equivalents and investments, and the revenue it expects to generate from XPOVIO product sales, as well as revenue generated from its license agreements, will be sufficient to fund its planned operations into late 2022"
Hab heute eine erste Position erworben. XPOVIO hat einiges an Potenzial. Und da sich der ramp-up in der 2. Jahreshälfte spürbar beschleunigen soll geh ich davon aus, dass spätestens dann neben den Zahlen auch das Sentiment rund um die Aktie besser sein wird.
davon XPOVIO® (selinexor) 20,2 Mio. $ (-7% zum Vorquartal)
Verlust 54 Mio. $
Cash 239 Mio. $
MK 587 Mio. $ (SK von gestern)
- Looking Forward to a Milestone-Driven Second Half of 2021, Including Top-Line Data from Phase 3 SIENDO Study in Endometrial Cancer and Initiations and Expansions of Key Clinical Trials in Myelodysplastic Syndrome, Myelofibrosis, Multiple Myeloma & Colorectal Cancer
Das sehen die Marktteilnehmer äußerst ungern, wenn die Umsatzzahlen eines neuen Produktes fallen statt zu steigen. Die Q1/21 Produktumsätze lagen bei 21,7 Mio. $.
Thread abonnieren
